Neurocrine Biosciences Inc. (NB3)
FSX
Closed
Aug 24, 2026
Day's Range
129.4052 wk Range
102.55Overview - NB3 - Neurocrine Biosciences Inc.
Key Statistics
Valuation
Enterprise Value
11.53B
P/E (Trailing)
‪22.53‬
P/E (Forward)
‪34.15‬
PEG Ratio
‪0.72‬
Price / Sales (TTM)
‪3.97‬
Price / Book
‪4.19‬
EV / EBITDA
‪14.75‬
Profitability
Gross Margin
‪97.58%‬
Profit Margin
‪20.91%‬
Operating Margin
‪22.19%‬
Return on Assets
‪11.70%‬
Return on Equity
‪22.08%‬
Ownership
Shares Outstanding
101.60M
Float
100.38M
Held by Insiders
‪1.06%‬
Held by Institutions
‪102.80%‬
Price stats
Beta
‪0.39‬
50-Day Avg
‪144.46‬
200-Day Avg
‪125.62‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - NB3 - Neurocrine Biosciences Inc.
Peers - NB3 - Neurocrine Biosciences Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on FSX.
- NB3FSXNeurocrine Biosciences Inc.13.44BMarket Cap+10.57%52-week change22.23P/E (Trailing)‪20.91%‬Profit Margin
- ANLFSXAnalog Devices, Inc.155.74BMarket Cap+33.03%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- PARFSXParker-Hannifin Corporation107.87BMarket Cap+24.53%52-week change35.09P/E (Trailing)‪16.96%‬Profit Margin
- MRKFSXMerck KGaA59.69BMarket Cap+19.31%52-week change23.51P/E (Trailing)‪11.21%‬Profit Margin
- MRKCFSXMerck KGaA – Sponsored ADR59.56BMarket Cap+19.71%52-week change23.62P/E (Trailing)‪11.21%‬Profit Margin
- PY3FSXGalderma Group AG42.44BMarket Cap+22.10%52-week change58.15P/E (Trailing)‪14.57%‬Profit Margin
- H6D0FSXHaleon plc37.06BMarket Cap+1.29%52-week change20.06P/E (Trailing)‪14.55%‬Profit Margin
Profile Summary - NB3 - Neurocrine Biosciences Inc.
About
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA (valbenazine), a VMAT2 inhibitor, addresses tardive…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
